30/04/2026
๐๐ฉ๐ซ๐ข๐ฅ was about one thing: ๐ค๐ง๐จ๐ฐ๐ข๐ง๐ ๐ฐ๐ก๐ข๐๐ก ๐ฆ๐๐ซ๐ค๐๐ญ๐ฌ ๐๐ซ๐ ๐ซ๐๐๐๐ฒ ๐๐จ๐ซ ๐ฒ๐จ๐ฎ ๐๐๐๐จ๐ซ๐ ๐ฒ๐จ๐ฎ ๐๐ง๐ญ๐๐ซ ๐ญ๐ก๐๐ฆ.
From ๐๐๐ฎ๐๐ข ๐๐ซ๐๐๐ข๐'๐ฌ ๐๐
๐๐ ๐ฉ๐ก๐๐ซ๐ฆ๐๐๐๐ฎ๐ญ๐ข๐๐๐ฅ ๐ซ๐๐ ๐ข๐ฌ๐ญ๐ซ๐๐ญ๐ข๐จ๐ง roadmap and the complexity of the region's largest drug market, to ๐๐๐'๐ฌ ๐๐๐๐ ๐ซ๐๐ ๐ฎ๐ฅ๐๐ญ๐จ๐ซ๐ฒ ๐ฉ๐๐ญ๐ก๐ฐ๐๐ฒ for cell and gene therapy manufacturers navigating the EU, this month mapped the frameworks shaping global market access.
We also decoded ๐๐๐๐ ๐๐ซ๐ฎ๐ ๐ซ๐๐ ๐ข๐ฌ๐ญ๐ซ๐๐ญ๐ข๐จ๐ง in Southeast Asia's largest pharma market, unpacked ๐๐๐
๐๐๐๐๐ ๐๐จ๐ฌ๐ฆ๐๐ญ๐ข๐ ๐๐ฉ๐ฉ๐ซ๐จ๐ฏ๐๐ฅ in Mexico, examined why ๐๐จ๐ฌ๐ฌ๐ข๐๐ซ ๐๐ฎ๐ญ๐จ๐ฆ๐๐ญ๐ข๐จ๐ง is rewriting drug approval timelines in 2026, and explored ๐ฏ๐๐ญ๐๐ซ๐ข๐ง๐๐ซ๐ฒ ๐ฉ๐ซ๐จ๐๐ฎ๐๐ญ ๐ซ๐๐ ๐ข๐ฌ๐ญ๐ซ๐๐ญ๐ข๐จ๐ง under ๐๐๐๐๐๐'๐ฌ ๐ฅ๐๐ญ๐๐ฌ๐ญ ๐๐ซ๐๐ฆ๐๐ฐ๐จ๐ซ๐ค in South Africa.
Explore ๐๐ฉ๐ซ๐ข๐ฅ'๐ฌ ๐ข๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ on our website: https://tinyurl.com/njwjyjzz.